2026-04-17T00:39:40Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/2231122025-12-05T00:26:38Zcom_2072_1057col_2072_478916col_2072_478917

Building the foundations for an organized population-based cervical cancer screening program with primary HPV self-sampling in Catalonia, Spain: findings from a pilot implementation study Peremiquel Trillas, Paula Roura Fornells, Esther Rangel Sarmiento, Valentina Morey, Francisca Font, Rebeca Carvajal Restoy, Maite Robles, Claudia Ibáñez, Raquel Pijuan, Lara Tamarit, Lourdes Cortasa, Dolça Fernández, Daniel Alfons Espinàs, Josep Bruni, Laia The Catalan Cervical Cancer Screening Program Working Group Càncer de coll uterí Papil·lomavirus Cribratge Cervix cancer Papillomaviruses Medical screening Introduction As part of the transition from opportunistic cytology-based screening to an organized, population-based HPV screening program, Catalonia, Spain, launched an implementation pilot in 2021.Methods The pilot combined home-based HPV self-sampling with pharmacy-based distribution, coordinated by a screening office using an SMS-based invitation and reminder system, alongside structured follow-up of HPV-positive cases by midwives.Results From July 2021 to December 2023, 6,355 women seeking cervical cancer screening were invited to participate in HPV self-sampling via SMS, with high participation (80.9%). Among HPV-positive women (11.8%), compliance with triage cytology was high (98.7%), as with colposcopy referrals when indicated (97.2%). CIN2+ detection rates (3.6% overall, 13.1% in HPV-16 positive) aligned with international studies, reinforcing the value of genotype-specific risk stratification and risk-adapted follow-up pathways in our setting. This organized approach facilitated timely case management and demonstrated the feasibility, acceptability, and effectiveness of the model.Discussion While conducted in an opportunistic screening context with a relatively short follow-up time, these findings support HPV self-sampling as an effective primary screening strategy, including women who regularly attend cervical cancer screening, and provide key insights for its scalability within a population-based program, which began its pilot phase in 2024 and is set for full implementation in 2025. 2025-09-12T07:05:44Z 2025-09-12T07:05:44Z 2025-08-04 2025-09-10T08:12:05Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Reproducció del document publicat a: https://doi.org/10.3389/fmed.2025.1580665 Frontiers in Medicine, 2025, vol. 12 https://doi.org/10.3389/fmed.2025.1580665 cc-by (c) Peremiquel Trillas, Paula et al., 2025 http://creativecommons.org/licenses/by/3.0/es/ info:eu-repo/semantics/openAccess Frontiers Media SA Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))